| The fact that induced-differentiation treatment of leukemia with all-trans retinoic acid (ATRA) was so succeeded that it was considered as a good example for tumor therapy, which has established a new way in the treatment of tumor. But the treatment of solid tumors by means of induced differentiation, has not been yet so broken-through at present. Cell differentiation agent-II ( CDA-II ) which comprised a varity of non-cytotoxicity anti-tumor activities by means of induced-differentiation is a natural components which has been extracted and purified from health human urine. However, the systemic investigation of the effect of CDA-II on breast cancer was not found up to now. In the present study the effects of CDA-II on the differentiation of breast carcinoma cell lines MCF-7 and MDA-MB-23 1 were observed in vitro cultures, in comparison with the classical cell differentiation inducer ATRA. MCF-7 and MDA-MB-23 1 have their different biologic characteristics. The impact of CDA-II on the morphology, cell cycle progression, cell apoptosis, cell differentiation as well as several cell differentiation correlating gene expression of breast cancer cell was systemically studied. The results demonstrated for the first time up to date , to the best of our knowledge, that CDA-II has not only remarkable antiproliferative effect, inducing tumor cells differentiation and apoptosis, regulating cell differentiation correlating gene (ICAM-K cyclinDK bcl-2) expression in this two different biologic characteristics breast cancer cell strains; but also that these kinds of action are reversible with depletion of CDA-II in culture medium. Our results provide comparatively systemic cellular and molecular bases for the treatment of breastcarcinoma with CDA-II and also suggest that CDA-II showed good prospects ofapplication for the treatment of breast carcinoma.
|
PDF Full Text Request